Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin and Metformin as Initial Therapy in Type 2 Diabetes
NCT02273050Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Dec 2014; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02273050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273050.